Retatrutide: Is It Available Yet, and Is It Safe to Buy Right Now?

Retatrutide gets talked about as the next big GLP-1 — a "triple agonist" with weight-loss numbers that beat both semaglutide and tirzepatide in early trials. It is not, as of this writing, an FDA-approved drug you can legally get prescribed and filled at a US pharmacy. That gap between hype and approval status is exactly where risk lives, and it's worth understanding precisely before you go looking for it.

What retatrutide actually is

Retatrutide is a triple-hormone-receptor agonist, activating GIP, GLP-1, and glucagon receptor pathways simultaneously — one more mechanism than tirzepatide (which activates two) and two more than semaglutide (which activates one)¹. In its phase 2 obesity trial, published in 2023, the numbers were striking: at 48 weeks, the highest dose (12 mg) produced 24.2% average weight loss versus 2.1% on placebo, and the 8 mg dose reached 22.8%¹. At the highest doses, the overwhelming majority of participants reached substantial weight-loss milestones — 100% reached at least 5% loss, and 83%-91% reached at least 15% loss at the top two doses, compared with a small fraction of the placebo group¹. Side effects tracked the same gastrointestinal pattern as other GLP-1-class drugs, dose-related and generally mild to moderate¹.

It's still in trials, not on the market

As of this writing, retatrutide is in Lilly's TRIUMPH registrational trial program — covering obesity, obstructive sleep apnea, and knee osteoarthritis as separate indications the company is pursuing², plus a dedicated chronic kidney disease trial (TRANSCEND-CKD)³. Registrational trials are the step that precedes an FDA approval application — they are not the same as approval, and there is no confirmed date for when, or whether, retatrutide will reach the market as an approved prescription drug.

What's actually being sold right now, and what "export only" means

Here's the part that should give you pause. A search of DailyMed — the National Library of Medicine's official drug-label database — currently returns listings for "Retatrutide Pen," "Retatrutide Lyophilized Powder," several "Salkalli" branded retatrutide products, and even an "Esokalli Slimming Microcrystalline Patch," all from a single labeler: Guangzhou Yixin Cross-border E-commerce Co., Ltd. Pulling the actual label for one of these products shows the marketing category listed as "Export only," with a marketing start date in late 2025 — meaning the product is explicitly not approved for US distribution or use, despite an NDC (National Drug Code) registration and a listed indication for "long-term weight management and reduction of visceral fat"⁴. An NDC number and a DailyMed listing are not the same thing as FDA approval — DailyMed hosts labels submitted by registrants, and a registrant can list a product as export-only while still describing therapeutic uses on the label. If you see retatrutide for sale online claiming to be the real thing, this is very plausibly where it's coming from, and "export only" is the manufacturer's own label telling you it isn't meant to end up in a US patient.

Why this matters more than a typical compounding question

Compounded semaglutide and tirzepatide, whatever their other issues, are at least copies of an FDA-approved active ingredient, made (ideally) by a licensed 503A or 503B pharmacy under pharmaceutical manufacturing standards — see how to verify a compounding pharmacy is legitimate for that checklist. Retatrutide sold online right now is a different category entirely: an unapproved drug, not compounded from an approved reference product, sourced through channels explicitly marked "export only" rather than for US medical use. There's no FDA safety or efficacy review behind what's in the vial, no guarantee of correct dosing or purity, and no legitimate US prescribing pathway to obtain it through a licensed pharmacy right now. That's a materially higher-risk category than even the compounding-legitimacy questions we cover in is cheap compounded GLP-1 safe? how to vet a low price.

What to do instead

If retatrutide's trial results are what's drawing you in, the honest answer is patience — wait for an actual FDA decision, which will also mean an FDA-reviewed safety and manufacturing standard behind whatever eventually reaches pharmacies. In the meantime, semaglutide and tirzepatide are the approved options with real trial data and real, regulated pharmacy channels behind them; see semaglutide vs tirzepatide: the cheaper effective GLP-1 for how those two compare, and check the current shortage and supply picture in GLP-1 shortage status: what the FDA actually declared and when.

Where this fits your decision

We don't rank or recommend any retatrutide source, compounded or otherwise, because there currently isn't a legitimate US prescribing pathway to vet. Compare approved, verified GLP-1 pricing instead on our semaglutide and tirzepatide boards, and see how we screen for legitimacy in our Value Score methodology.

This piece sits in our research index alongside every other sourced explainer we publish — the trials, the compounding rules and the pricing mechanics, grouped by the question each one answers.